In Vivo Therapeutic Cell Tracking by Advanced Magnetic Particle Imaging

通过先进的磁粒子成像进行体内治疗细胞追踪

• 批准号: 9368802
• 负责人: STEVEN M CONOLLY
• 金额: $ 48.56万
• 依托单位: UNIVERSITY OF CALIFORNIA BERKELEY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-01 至 2021-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9368802
• 关键词: Adoption; Affect; Air; Animals; Back; Biomechanics; Cell Death; Cell Survival; Cell Therapy; Cells; Clinical; Contrast Sensitivity; Core Facility; Data; Demyelinating Diseases; Detection; Discipline of Nuclear Medicine; Dose; Electronics; Event; Faculty; Goals; Image; Imaging Device; Imaging Techniques; Imaging technology; Ligand Binding; Magnetic Resonance Imaging; Magnetism; Measurement; Measures; Methods; Modality; Mus; Nuclear; Optics; Organ; Physics; Physiologic pulse; Positioning Attribute; Protocols documentation; Publishing; Radiation; Relaxation; Reporting; Research; Resolution; Safety; Scanning; Signal Transduction; Stem cells; Techniques; Therapeutic; Time; Tissues; Tomography, Computed, Scanners; Tracer; Treatment Efficacy; Ultrasonography; Viscosity; X-Ray Computed Tomography; bone; cellular imaging; image reconstruction; imaging modality; improved; in vivo; in vivo Model; innovation; iron oxide; mouse model; nanoparticle; non-invasive imaging; particle; pre-clinical; professor; prototype

Abstract Cell therapies have been held back by serious challenges in achieving specific delivery to the damaged organ, realizing treatment efficacy, and safety concerns. A noninvasive imaging technique that could follow a sub-therapeutic dose (say 10 cells) anywhere in the body, and report back on the cells' viability, could greatly expedite protocol optimization and hasten cellular therapy clinical adoption. Today's whole-animal cell tracking imaging methods (e.g., MRI, optical, ultrasound, nuclear medicine) all have their strengths and technical limitations. A new noninvasive imaging method called Magnetic Particle Imaging (MPI) uses zero radiation. MPI shows extraordinary promise as a complementary cell tracking and reporting method. Just to be clear, MPI images cannot be obtained in an MRI scanner. This year, our group at Berkeley showed MPI tracking of stem cells for the first time in live animals, with quantitative 200-cell “positive contrast” sensitivity. MPI shows ideal, quantitative contrast with no confounds near air or bone as in other modalities. MPI is already 100-times more sensitive than today's noninvasive cell imaging methods, and here we aim to make it even more sensitive. Both the 200-cell sensitivity and MPI's spatial resolution can still be greatly improved. Our overall aim is to improve MPI to reach the true physics limits of MPI, specifically 20-cell detection and 280-micron spatial resolution. Finally, we plan to validate these innovations by tracking an in vivo model of stem cell treatment for demyelinating disease with stem cell expert, UC Berkeley Professor David Schaffer.

摘要 细胞疗法在实现特定的fi-c递送到受损的患者方面受到严重挑战的阻碍。 器官，实现治疗fi的安全性和安全性。一种可能遵循的非侵入性成像技术 体内任何地方的亚治疗剂量(比方说10个细胞)，并报告细胞的存活情况，可能会 极大地加快了方案优化，加速了细胞疗法的临床采用。 今天的全动物细胞跟踪成像方法(例如，MRI、光学、超声、核医学)都 都有自己的长处和技术局限性。一种新的非侵入性成像方法--磁粉 成像(MPI)使用零辐射。MPI作为一种补充细胞跟踪显示出非凡的前景 和报道方法。需要说明的是，MPI图像不能在核磁共振扫描仪中获得。今年, 我们在伯克利的团队首次在活体动物中展示了对干细胞的MPI跟踪，并进行了定量 200个细胞的“阳性对比”灵敏度。MPI显示理想的定量对比，在空气或 与其他形式的骨骼一样。MPI已经比今天的非侵入性细胞成像灵敏100倍 方法，在这里我们的目的是使它更敏感。200个电池的灵敏度和MPI的空间 分辨率仍然可以大大提高。我们的总体目标是改进MPI，使其达到真正的物理极限 在MPI方面，SPECIfi具有20个细胞的检测能力和280微米的空间分辨率。最后，我们计划验证这些 追踪干细胞治疗脱髓鞘疾病体内模型的创新 加州大学伯克利分校专家大卫·谢弗教授。